Benefits With Gilteritinib for AML Were Maintained, Regardless of Co-Mutations

The survival benefit observed with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia in the ADMIRAL trial was maintained regardless of the presence of several common co-mutations.

Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news